Pneumococcus is one of the most common bacterial pathogens encountered in medicine. This article summarizes the risk factors, pathogenesis, treatment, and prevention of the spectrum of disease caused by pneumococcus with particular emphasis on antibiotic resistance as well as immunization. This information is useful for physicians caring for patients both as inpatients and outpatients as well as for those concerned with public health and disease prevention.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.mcna.2013.03.005 | DOI Listing |
J Infect Public Health
January 2025
Department of Paediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Mary Elizabeth's Hospital, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Electronic address:
Background: Respiratory infections substantially impact pediatric health. The COVID-19 pandemic introduced widespread non-pharmaceutical interventions, which influenced the incidence of common respiratory infections. This comprehensive study investigates the impact of these interventions on the incidence of respiratory syncytial virus, influenza, and invasive pneumococcal disease in Danish children.
View Article and Find Full Text PDFAntimicrob Agents Chemother
January 2025
Norton Infectious Diseases Institute, Norton Healthcare, Louisville, Kentucky, USA.
Omadacycline is a novel antimicrobial belonging to the tetracycline class. It has the ability to evade both efflux and ribosomal methylation types of resistance and therefore has an expanded spectrum compared to other tetracycline agents. Omadacycline is active against a number of multidrug-resistant bacteria, including macrolide and doxycycline-resistant methicillin-resistant (MRSA), vancomycin-resistant Enterococcus, and several enteric gram-negative bacilli.
View Article and Find Full Text PDFOpen Forum Infect Dis
January 2025
Harvard Medical School, Boston, Massachusetts, USA.
Background: Infections by and influenza viruses are vaccine-preventable diseases causing great morbidity and mortality. We evaluated pneumococcal and influenza vaccination practices during pre-international travel health consultations.
Methods: We evaluated data on pretravel visits over a 10-year period (1 July 2012 through 31 June 2022) from 31 sites in Global TravEpiNet (GTEN), a consortium of US healthcare facilities providing pretravel health consultations.
Microbiol Spectr
January 2025
Sunshine Coast Health Institute, Birtinya, Queensland, Australia.
Pleural infections are common and associated with substantial healthcare costs, morbidity, and mortality. Accurate diagnosis remains challenging due to low culture positivity rates, frequent polymicrobial involvement, and non-specific diagnostic biomarkers. Here, we undertook a prospective study examining the feasibility and performance of molecular methods for diagnosing suspected pleural infection.
View Article and Find Full Text PDFArch Bronconeumol
January 2025
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain; University of Barcelona, Barcelona, Spain; Ciber de Enfermedades Respiratorias (Ciberes), Barcelona, Spain. Electronic address:
Background: Polymicrobial pneumonia is a concern for clinicians due to its association with increased disease severity. Determining the prevalence of polymicrobial pneumonia and identifying patients who have an increased risk of this aetiology is important for the management of CAP patients. Here we describe the clinical characteristics and outcomes of adult hospitalized patients with CAP, and identify the risk factors related to polymicrobial pneumonia and specifically to 30-day mortality.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!